Joel Beatty
Stock Analyst at Baird
(4.57)
# 243
Out of 5,135 analysts
208
Total ratings
50.61%
Success rate
33.19%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $72 → $47 | $20.45 | +129.83% | 5 | Dec 30, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Outperform | $16 → $14 | $15.17 | -7.71% | 3 | Nov 24, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $160 → $209 | $168.72 | +23.87% | 5 | Nov 18, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $145 → $125 | $88.04 | +41.98% | 9 | Nov 6, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $10 → $19 | $14.10 | +34.75% | 5 | Oct 16, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $10 → $7 | $2.95 | +137.29% | 3 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $47.47 | +41.14% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $1.72 | +248.84% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $38.35 | -76.53% | 6 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $23.19 | +33.68% | 4 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $24 | $17.21 | +39.45% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $680 | $845.35 | -19.56% | 7 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $29 | $19.23 | +50.81% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $66 | $68.93 | -4.25% | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $184.74 | -12.31% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $32.02 | +28.04% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $328.93 | -77.81% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $24.29 | +31.74% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $80.30 | -6.60% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $2.80 | +150.00% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $61.83 | +5.13% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $0.75 | +31,895.73% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.94 | +131.96% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $15.48 | +61.50% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $20.25 | +38.27% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.35 | +1,085.19% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.32 | -5.30% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.25 | +3,420.00% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $64.38 | -9.91% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $30.92 | -22.38% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $7.51 | +139.68% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $1.56 | +284.62% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $7.83 | +257.60% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $332.68 | -47.40% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $6.03 | +132.17% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $18.38 | +487.60% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $82.22 | -5.13% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $20.53 | +387.09% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $15.76 | +661.42% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $2.99 | +14,950.17% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.57 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $8.69 | +72.61% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $11 | $11.20 | -6.25% | 8 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2,400 → $1,200 | $0.22 | +545,354.55% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $8.49 | +123.79% | 3 | Nov 10, 2017 |
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $72 → $47
Current: $20.45
Upside: +129.83%
Contineum Therapeutics
Nov 24, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $15.17
Upside: -7.71%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160 → $209
Current: $168.72
Upside: +23.87%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145 → $125
Current: $88.04
Upside: +41.98%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10 → $19
Current: $14.10
Upside: +34.75%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $2.95
Upside: +137.29%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $47.47
Upside: +41.14%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $1.72
Upside: +248.84%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $38.35
Upside: -76.53%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $23.19
Upside: +33.68%
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $17.21
Upside: +39.45%
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $845.35
Upside: -19.56%
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $19.23
Upside: +50.81%
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $68.93
Upside: -4.25%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $184.74
Upside: -12.31%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $32.02
Upside: +28.04%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $328.93
Upside: -77.81%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $24.29
Upside: +31.74%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $80.30
Upside: -6.60%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $2.80
Upside: +150.00%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $61.83
Upside: +5.13%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $0.75
Upside: +31,895.73%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.94
Upside: +131.96%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $15.48
Upside: +61.50%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $20.25
Upside: +38.27%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $1.35
Upside: +1,085.19%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.32
Upside: -5.30%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.25
Upside: +3,420.00%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $64.38
Upside: -9.91%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $30.92
Upside: -22.38%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $7.51
Upside: +139.68%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $1.56
Upside: +284.62%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $7.83
Upside: +257.60%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $332.68
Upside: -47.40%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $6.03
Upside: +132.17%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $18.38
Upside: +487.60%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $82.22
Upside: -5.13%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $20.53
Upside: +387.09%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $15.76
Upside: +661.42%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $2.99
Upside: +14,950.17%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.57
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $8.69
Upside: +72.61%
Aug 17, 2018
Upgrades: Neutral
Price Target: $14 → $11
Current: $11.20
Upside: -6.25%
Aug 17, 2018
Maintains: Neutral
Price Target: $2,400 → $1,200
Current: $0.22
Upside: +545,354.55%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $8.49
Upside: +123.79%